corner
Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library item: 6038

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

 

Publication type: Journal Article

Kassirer JP, Angell M.
The journal's policy on cost-effectiveness analyses.
N Engl J Med 1994 Sep 8; 331:(10):669-70


Abstract:

Cost decisions about the use of drugs and othe therapeutic interventions are increasingly being influenced by cost-effectiveness analyses. Because of the discretionary nature of the methods used to analyze cost effectiveness and the increasing importance of such analyses it is incumbent on authors, journal editors and the funders of these studies to minimize any source of bias. In this editorial the New England Journal of Medicine announces its policy on acceptance of cost-effectiveness studies.

Keywords:
*editorial/New England Journal of Medicine/ conflict of interest/ pharmacoeconomic analysis/ drug company sponsored research/scientific publications/REGULATION, CODES, GUIDELINES: JOURNALS AND MASS MEDIA

 

  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Please
Click to Register

(read more)

then
Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts


If there is something you don't like, please tell us. If you like our work, please tell others.

Email a Friend








...to influence multinational corporations effectively, the efforts of governments will have to be complemented by others, notably the many voluntary organisations that have shown they can effectively represent society’s public-health interests…
A small group known as Healthy Skepticism; formerly the Medical Lobby for Appropriate Marketing) has consistently and insistently drawn the attention of producers to promotional malpractice, calling for (and often securing) correction. These organisations [Healthy Skepticism, Médecins Sans Frontières and Health Action International] are small, but they are capable; they bear malice towards no one, and they are inscrutably honest. If industry is indeed persuaded to face up to its social responsibilities in the coming years it may well be because of these associations and others like them.
- Dukes MN. Accountability of the pharmaceutical industry. Lancet. 2002 Nov 23; 360(9346)1682-4.